Who Gets Prescribed Peptides: Six Months of Telehealth Data From 2,500 Patients
Rx Peps Direct looked at every approved prescription order from its first patients in May 2026 through November 18, 2026: 2,506 patients. The median patient is 45, and only 7.5% are under 30. Six in ten have never ordered a weight-loss product, and men and women order markedly different peptides.
6 min read · Updated November 18, 2026
- median age at first order
- 45
- median age at first order
- of patients are under 30
- 7.5%
- of patients are under 30
- have never ordered a weight-loss product
- 59.8%
- have never ordered a weight-loss product
Key numbers
2,506 patients, May 13 to November 18, 2026. Each row can be linked on its own by adding its anchor to this page's address, for example #median-age.
| Finding | Figure | Out of |
|---|---|---|
| Median age at first order | 45 | 2,506 patients |
| Patients aged 40 to 59 | 58.2% | 1,458 of 2,506 patients |
| Patients aged 50 or older | 35.7% | 895 of 2,506 patients |
| Patients under 30 | 7.5% | 189 of 2,506 patients |
| Never ordered a weight-loss product | 59.8% | 1,498 of 2,506 patients (men 69.2%, women 46.5%) |
| Ordered a product containing BPC-157 or TB-500 | 48.4% | 1,214 of 2,506 patients |
| Women and men | 42% / 58% | 1,045 women, 1,460 men |
| Women's share of GHK-Cu patients | 61.2% | 423 patients |
| Women's share of GLP-1 patients | 59.4% | 764 patients |
| Men's share of growth-hormone-releasing peptide patients | 76.2% | 719 patients |
| Had a second order approved, among patients whose first order was 60 or more days earlier | 65.2% | 733 of 1,124 patients |
How old are peptide patients?
The median patient was 45 at their first order and the mean was 47.9. More than half (58.2%) were 40 to 59, more than a third (35.7%) were 50 or older, and only 7.5% were under 30. The 40s are the largest group, at 34.0% of patients.
| Age at first order | Patients | Share |
|---|---|---|
| 18 to 29 | 189 | 7.5% |
| 30 to 39 | 569 | 22.7% |
| 40 to 49 | 853 | 34.0% |
| 50 to 59 | 605 | 24.1% |
| 60 to 69 | 218 | 8.7% |
| 70 and older | 72 | 2.9% |
The women skew older too: 69% of them (721 of 1,045) were 40 or older at their first order.
How many patients have ordered a weight-loss product?
About four in ten. The other 59.8% (1,498 of 2,506) have never had a weight-loss product approved: 69.2% of men and 46.5% of women.
Do men and women order different peptides?
Yes. Patients are 58% men and 42% women, but some product groups lean much further one way.
| Product group | Patients | Who orders it |
|---|---|---|
| Wolverine stack (BPC-157 and TB-500) | 368 | 80.7% men |
| Growth-hormone-releasing peptides | 719 | 76.2% men |
| NAD+ injection | 359 | 52.1% women |
| GLP-1s (tirzepatide, semaglutide) | 764 | 59.4% women |
| GHK-Cu, injectable and topical | 423 | 61.2% women |
The study records who orders what. It does not record why.
How many patients ordered BPC-157 or TB-500?
48.4% (1,214 of 2,506) ordered at least one product containing BPC-157 or TB-500, including the KLOW and Wolverine blends. Our most popular peptides analysis ranks the individual products.
Do patients come back?
Two in three do. Of the 1,124 patients whose first order was at least 60 days before November 18, 65.2% (733) have had a second order approved.
Methodology
A de-identified, aggregate analysis of approved prescription orders at one U.S. telehealth practice. Figures describe Rx Peps Direct patients only and are not a national estimate.
| Records | Every approved prescription order at Rx Peps Direct from its first patients (May 13, 2026) through November 18, 2026. |
|---|---|
| Patients | Counted once each, matched by name and date of birth: 2,506 patients. |
| Age | Age at the patient's first approved order, from the date of birth entered at intake. |
| Sex | Biological sex as entered at intake: 1,460 men and 1,045 women. One patient who chose another answer is left out of the splits by sex. |
| Products | Grouped from the product names on each approved order, across doses and forms. |
| Privacy | Only aggregate counts were pulled. No individual patient can be identified from these figures, and the smallest group reported is 72 patients. |
How the product groups are defined
| Weight-loss products | Tirzepatide, semaglutide, AOD-9604, 5-Amino-1MQ, tesofensine, the Lean Stacks and lipotropic (Lipo-B and Lipo-C) injections |
|---|---|
| GLP-1s | Tirzepatide and semaglutide, in every form |
| Growth-hormone-releasing peptides | CJC-1295/ipamorelin, tesamorelin, sermorelin and their ipamorelin combinations. The Lean Stacks are not counted here. |
| BPC-157 or TB-500 | Any product containing either: BPC-157, TB-500, KLOW and the Wolverine stack, in every form |
| GHK-Cu | Injectable GHK-Cu and the GHK-Cu creams, serums and hair solution |
This study counts approved orders and matches patients by name and date of birth. Our earlier most popular peptides analysis counted every paid order and matched patients by email, so its figures differ slightly.
Limits
- These are the patients of one telehealth practice, which prescribes in 28 states plus Washington, DC. They are not a national estimate of who uses peptides.
- Only approved orders count. Orders a provider did not approve, and orders still under review, are left out.
- Matching by name and date of birth can count one person twice if they entered their name two ways.
- Age and sex are what patients entered at intake.
- Patients can only order what Rx Peps Direct prescribes, so the product mix reflects its catalog.
How to cite this study
Rx Peps Direct, "Who Gets Prescribed Peptides: Six Months of Telehealth Data From 2,500 Patients," November 18, 2026, https://www.rxpepsdirect.com/learn/who-gets-prescribed-peptides-2026
Reporters may quote any figure on this page with that credit and a link to this page.
Media contact
Marcus Hansen, Founder and CEO, Rx Peps Direct: support@rxpepsdirect.com. The full de-identified breakdown is available on request.
Dr. Jonathan Snipes, Medical Director and co-founder of Rx Peps Direct, is available for clinical questions. Marcus Hansen answers questions about the data.
About Rx Peps Direct
Rx Peps Direct (RxPepsDirect.com) is a telehealth practice that provides prescriptions for pharmaceutical-grade compounded peptides in 28 states plus Washington, DC. Patients pay a single $39 medical review fee. Rx Peps Direct sends every prescription to a licensed U.S. 503A compounding pharmacy, which fills it and ships it directly to the patient, and the patient pays the pharmacy at its wholesale price. Rx Peps Direct prescribes only non-controlled peptides. Compounded medications are not FDA-approved.
Continue reading